Nephroprotective Effects of *Dioscoreaalata* and *Moriengaolifera* on Cisplatin Induced Nephrotoxicity in Rats

A. K. M. Shahidur Rahman,1 Anwar Habib,2 Nishat Parvin,3 Monjurur Rahman Shah Chowdhury4

Abstract

Nephrotoxicity, which is caused by mostly due to medication, is one of most important global health problem. Drugs are a common source of acute kidney injury. Drugs shown to cause nephrotoxicity exert their toxic effects by one or more common pathogenic mechanisms. Most drugs found to cause nephrotoxicity exert toxic effects by one or more common pathogenic mechanisms. These include altered intraglomerular hemodynamics, tubular cell toxicity, inflammation, crystal nephropathy, rhabdomyolysis, and thrombotic microangiopathy. Drug-induced nephrotoxicity tends to be more common among certain patients and in specific clinical situations. Cisplatin, one of the many drugs, is responsible for severe nephrotoxicity. General preventive measures to avoid nephrotoxicity include using alternative non-nephrotoxic drugs; correcting risk factors; assessing baseline renal function before initiation of therapy, followed by adjusting the dosage; monitoring renal function and vital signs during therapy; and avoiding nephrotoxic drug combinations, using of several nephroprotective agents including medicinal plant extracts. Promising results showed that the use of some medicinal plant extracts (*Dioscoreaalata* and *Moriengaolifera*) gave rise to moderate restoration of normal physiology of kidney and liver of mice.

Key words: Nephroprotective, *Dioscoreaalata*, *Moriengaolifera*, cisplatin, rat.

Introduction

The kidney is an essential organ required by the body to perform several important functions including the maintenance of homeostasis, regulation of the extracellular environment, such as detoxification, and excretion of toxic metabolites and drugs. Therefore, the kidney can be considered as a major target organ for exogenous toxicants. Nephrotoxicity is a kidney-specific feature in which excretion does not go smoothly owing to toxic chemicals or drugs. Approximately 20% of nephrotoxicity is induced by drugs, but medication of the elderly increases the incidence of nephrotoxicity up to 66% as the average life span increases. Chemotherapy or anticancer medicine has been of limited use due to nephrotoxicity. However, these assessments of nephrotoxicity are only possible when a majority of kidney function is damaged.

Mechanism of Drug-induced nephrotoxicity

Cisplatin is cleared by the kidney by both glomerular filtration and tubular secretion. Cisplatin concentrations within the kidney exceed those in blood suggesting an active accumulation of drug by renal parenchymal cells. Previous studies using kidney slices, cultured renal

1 Associate Professor and Head, Department of Pharmacology & Therapeutics, Khwaja Younus Ali Medical College, Sirajganj, Bangladesh
2 Professor, Department of Pharmacology & Therapeutics, Barind Medical College, Rajshahi, Bangladesh
3 Associate Professor, Dental Unit, Rajshahi Medical College, Rajshahi, Bangladesh
4 Associate Professor, Islami Bank Medical College, Rajshahi, Bangladesh
epithelial cells\textsuperscript{10} and isolated perfused proximal tubule segments\textsuperscript{11} have provided evidence for basolateral-to-apical transport of cisplatin. Studies in recent years have identified two different membrane transporters capable of transporting cisplatin into cells: Ctr1 and OCT2. Ctr1 is a copper transporter which was also shown to mediate cisplatin uptake into mammalian cells\textsuperscript{12}, including ovarian cancer cells.\textsuperscript{13} Ctr1 is highly expressed in adult kidney and the protein localizes to the basolateral membrane of the proximal tubule.\textsuperscript{14} Downregulation of Ctr1 expression in kidney cells \textit{in vitro} decreased both cisplatin uptake and cytotoxicity, suggesting that Ctr1 is an important cisplatin uptake mechanism in these cells.\textsuperscript{14} The role of Ctr1 in cisplatinum nephrotoxicity \textit{in vivo} has not been examined. In addition, the organic cation transporter OCT2 (SLC22A2) transports cisplatin.\textsuperscript{15-18}

Cisplatin was shown to inhibit the uptake of other OCT2 substrates, consistent with the view that these substrates share a common transport pathway. Likewise, cimetidine, an OCT2 substrate, reduced cisplatin uptake and cytotoxicity \textit{in vitro}\textsuperscript{15-17} and cisplatin nephrotoxicity \textit{in vivo}.\textsuperscript{7}

**Prevention of cisplatin induced nephrotoxicity, several approach**

Many strategies have attempted to prevent or reduce its nephrotoxicity.\textsuperscript{19,20} Early experience suggested that the administration of cisplatin by prolonged continuous infusion and saline hyperhydration, with or without frusemide or mannitol osmotic diuresis, reduces nephrotoxicity.\textsuperscript{19} Amongst many others, the drugs studied have included a variety of sulfur-containing compounds, such as sodium thiosulfate, WR-2721 (amifostine), DDTC (sodium diethyldithiocarbamate), mesna, biotin, cephalixin and sulfathiazole, all of which probably react with nephrotoxic cisplatin metabolites to form less toxic products.\textsuperscript{20,21}

**Protective effects of plants materials in drug-induced nephrotoxicites**

Several medicinal plants extract were used to prevent cisplatin induced nephrotoxicity. One study suggested that protective effect of terpenes isolated from the fruiting bodies of \textit{Ganoderma lucidum} (Fr) P. Karst found promising reduction of nephrotoxicity caused by the cisplatin, in mice. Intraperitoneal administration of cisplatin (16 mg/kg body wt) resulted in significant nephrotoxicity in mice. The results suggest the potential therapeutic use of \textit{Ganoderma terpenes} to prevent nephrotoxicity caused during chemotherapy using cisplatin.\textsuperscript{22}

One study suggested that after treatment with MNLE (methanolicneem leaves extract), the histological damage and apoptosis induction caused by cisplatin were improved.\textsuperscript{23}

One study suggested that, \textit{Taxilli Ramulus} could protect against cisplatin induced acute renal failure in mice.\textsuperscript{24-26}

Many other herbal medicines such as \textit{Dioscorea species} may reduce cisplatin induced nephrotoxicities has been reported. One study revealed that \textit{Morienga oleifera} seed powder at the dose rate of 600 mg/kg is as efficacious as silymarin in exerting nephroprotective and antioxidant effects.\textsuperscript{27} We reviewed clinical and experimental literature on cisplatin nephrotoxicity to identify new information on the mechanism of injury and further study will be emphasis the potential approaches on some medicinal plants \textit{Dioscoreaalata} and \textit{Moringaolifera}.\textsuperscript{27-31}

**Place and duration of the research work:** This research work was carried out in a) Indoor patient Department, Department of Oncology, Khwaja Yunus Ali Medical College, Hospital, Enayetpur, Sirajgonj. b) Centre for bioequivalence study, Khwaja Yunus Ali Medical College Hospital, Enayetpur, Sirajgonj c) Pharmacology Research Lab., Department of Pharmacology and Histology Laboratory of Anatomy of BSMMU, Shahbag, Dhaka from January 2012 to December 2014.
Materials and Methods

a) Methanolic extract of tuber part of the Dioscoreaalata and seed pods of Moringaoleifera.

b) Cisplatin induced liver and kidney of rat

1. Phytochemical investigation

Collection and identification of plant materials (tuber parts of Dioscoreaalata and seed pods of Moringaoleifera), Drying, Grinding and weighting of plant material. Extraction of plant materials with MeOH, Collection of powdered material from plant extracts-After evaporation gummy part of tuber parts of Dioscoreaalata and seed pods of Moringaoleifera were collected from the wall of volume flask weighted to 56 g and 34 g respectively. Two extracts were preserved in two separate air tight bottle for future biological investigations.

2. Histopathology of liver and kidney of Swiss albino rat

The most common procedure used in histologic research is the preparation of tissue sections or slices that can be studied with the light microscope. Under the light microscope, tissues are examined visually in a beam of transmitted light. Because most tissues and organs are too thick to pass through them, they must be sliced to obtained thin, translucent sections that are attached to glass slides for microscopic examination.

Collection of rats

Animal House, ICDDR’B, Mohakhhal, Dhaka. (vide memo no. 0461). Total number of test animal (Swiss albino rats): 40. Average wt of rat: 130 g. Total number of groups =4. Group A- Cisplatin, Group B- Cisplatin + D. alata, Group C- Cisplatin + Moringaoleife, Group D- Placebo control.

Animal Dose & Duration: A. Injectable : (a) Cisplatin :16 mg / kg body wt, given every weeks for 2 weeks. (b) Metabolite 2: 16 mg / kg body wt, given every weeks for 2 weeks.

(c) Metabolite 4: 16 mg / kg body wt, given every weeks for 2 weeks. B. Powdered extract: 250mg/kg body-wt.

Steps in preparation of Slides

I. Sectioning of Tissue- Paraffin sectioning: The steps in paraffin sectioning are-a. Fixation of the Tissue: Formal-saline (Formalin 10 ml and normal saline 90 ml) is commonly used as a used as a fixative b. Dehydration of the tissue in ethyl alcohol and xylol c. Preparation of Block-The tissue is casted in wax. d. Section cutting- Sections are cut with microtome and taken on slide.

II. Staining of the sections by- Haematoxylin and Eosin (H & E) Stains. Characteristics of Haematoxylin and Eosin (H & E) Stains are- 1. Nuclei stain blue. 2. Cytoplasm stain pink or red. 3. Collagen fibers stain pink. 4. Muscle stain pink.

Steps of preparing histological slide- 1. Treat with xylol to remove wax. 2. Treat with alcohol to remove xylol. 3. Rinse in water. 4. Stain in haematoxylin for 15-30 minutes. 5. Rinse in water for 15-30 minutes. 6. Differentiate in acid-alcohol till nuclei are only stained. 7. Rinse in water for 20-30 minutes. 8. Stain in 1% eosin for 5-15 minutes. 9. Wash in running water till eosin is differentiated. 10. Blot, dehydrate in alcohol, clear in xylol. 11. Mount the section in Canada balsam on a slide.
Results:

Photograph 1: Histopathology of liver and kidney of mouse after cisplatin administration.

Liver | Kidney | Liver | Kidney | Liver | Kidney
--- | --- | --- | --- | --- | ---
Group A | Group B | Group C

Results of histopathological changes in cisplatin-induced liver and kidney of rat. Group A showed normal findings of liver architecture and proximal tubular necrosis in kidney. While group B and group C, treated with extracts of D. alata and Maringa olifera, showed restoration of normal proximal tubular cells though moderate tubular necrosis were seen.

Table 1: Histopathology of liver and kidney of rat after cisplatin administration

| Drug | Liver | Kidney |
|------|-------|--------|
| Cisplatin | Normal findings of liver architecture. | Proximal tubular necrosis – some proximal tubular cells became swollen and some of the cell’s nucleus became shrinkaged (pyknotic cell) |

in group B and group C that was treated with extract of D. alata and extract of Maringa olifera has showed restoration of normal proximal tubular cells though moderate tubular necrosis were seen (Table 1-4).

Table 2: Histopathology of cisplatin treated liver and kidney of rat after D. alata extract administration

| Drug | Liver | Kidney |
|------|-------|--------|
| Cisplatin and D. alata extract | No changes were found in liver architecture. | Moderate amount of tubular necrosis were found. Rest of the tubular proximal cells became normal. Some of the proximal tubules show pyknotic cells and some are enucleated cells, some were swollen. |

Table 3: Histopathology of cisplatin treated liver and kidney of rat after M. olifera extract administration

| Drug | Liver | Kidney |
|------|-------|--------|
| Cisplatin and M. olifera extract | Normal hepatocytes was seen | Moderate amount of tubular necrosis were found. Rest of the tubular proximal cells became normal. Some of the proximal tubules show pyknotic cells and some are enucleated cells, some were swollen. |
**Discussion**

Massive necrosis of the proximal convoluted tubules with distorted cellular architecture along with other distal tubular abnormalities were seen the rat groups that was treated with cisplatin. A promising results showed that the use of some medicinal plant extracts (*D. alata* and *Moriengaolifera*) gave rise to moderate restoration of normal physiology of kidney and liver of rat (Photograph 1 & Figure 1-4).

The experimental results reveal that, the methanolic extract of *D. alata* and *M. olifera* could help prevent nephrotoxicity manifested consequent to cisplatin chemotherapy. The effect is mainly due to the capacity of the extract to restore renal antioxidant defense system. Our earlier investigations have shown that of methanol extract of *D. alata* and *M. olifera* occurring in South India possessed significant antioxidant and antitumour activities. Further study concerning the structure of suspected metabolites will be elucidated by using HPLC-mass spectrometry.

**Conclusion**

The extracts of *D. alata* and *Moriengaolifera* had some effects on renal histology in injured mice kidney was very promising and significant. Results suggest that *D. alata* and *Moriengaolifera* extract may be used to cure or prevent not only cisplatin-induced renal toxicity but also other drug induced nephrotoxicities without any adverse effect; hence it can serve as a novel combination agent with cisplatin and other drugs to limit renal injury.

**Acknowledgement**

The authors are very grateful to Prof. Dr. M. A. Awal, Professor & HOD, Department of Pharmacology for his valuable suggestions, critics and supplying different documents regarding this research work beneficial for conducting the research work.

**References**

1. Ferguson MA, Vaidya VS, Bonventre JV; Biomarkers of nephrotoxic acute kidney injury. Toxicology. 2008 Mar 20; 245(3):182-93.
2. Finn W, Porter G. Urinary biomarkers and nephrotoxicity. Clinical Nephrotoxins. 2nd ed Kluwer Academic Publishers; Massachusetts.: (2003). pp. 621–655.
3. Kohli HS, Bhaskaran MC, Muthukumar T, Thennarasu K, Sud K, Jha V, Gupta KL, Sakhija V; Treatment-related acute renal failure in the elderly: a hospital-based prospective study, Nephrol Dial Transplant. 2000 Feb; 15(2):212-7.
4. Naughton CA, Drug-induced nephrotoxicity. Am Fam Physician. 2008 Sep 15; 78(6):74-50.
5. Rached E, Hoffmann D, Blumbach K, Weber K, Dekant W, Mally A; Evaluation of putative biomarkers of nephrotoxicity after exposure to ochratoxin a in vivo and in vitro. Toxicol Sci.2008 Jun; 103 (2): 371-81.
6. Filipski K.K., Mathijssen R.H., Mikkelsen T.S., Schinkel A.H., Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin.Pharmacol. Ther. 2009;86:396–402.
7. Ciarimboli G., Deuster D., Knief A., Sperling M., Holtkamp M., Edemir B., Pavenstadt H., Lanvers-Kaminsky C., am Zehnhooff-Dinnesen A., Schinkel A.H., Koepsell H., Jurgens H., Schlatter E. Organic cation transporter 2 mediates cisplatin-induced ototoxic and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 2010;176:1169–1180.
8. Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin nephrotoxicity: A review. Am. J. Med. Sci. 2007;334:115–124.
9. Safirstein R., Miller P., Guttenplan J.B. Uptake and metabolism of cisplatin by rat kidney. Kidney Int. 1984;25:753–758.
10. Endo T., Kimura O., Sakata M. Carrier-mediated uptake of cisplatin by the OK renal epithelial cell line. Toxicology. 2000;146:187–195.
11. Kolb R., Ghazi M., Barfuss D. Inhibition of basolateral transport and cellular accumulation ofcisplatin and N-acetyl-L-cysteine-cisplatin by TEA and PAH in the renal proximal tubule. Cancer Chemother.Pharmacol. 2003;51:132–138.
12. Ishida S., Lee J., Thiele D.J., Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. USA. 2002;99:14298–14302.
13. Holzer A.K., Samimi G., Katano K., Naerdemann W., Lin X., Safaei R., Howell S.B. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol. Pharmacol. 2004;66:817–823.
14. Pabla N., Murphy R.F., Liu K., Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am. J. Physiol. Renal Physiol. 2009;296:F505–F511.
15. Ludwig T., Riethmuller C., Gekle M., Schwerdt G., Oberleithner H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int. 2004;66:196–202.

16. Ciarimboli G., Ludwig T., Lang D., Ravenstadt H., Koepsell H., Piechota H.J., Haier J., Jaehde U., Zisowsky J., Schlatter E. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 2005;167:1477–1484.

17. Filipski K.K., Loos W.J., Verweij J., Sparreboom A. Interaction of Cisplatin with the human organic cation transporter 2. Clin. Cancer Res. 2008;14:3875–3880.

18. Yonezawa A., Masuda S., Yokoo S., Katsura T., Inui K.-i. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family) J. Pharmacol. Exp. Ther. 2006;319:879–886.

19. Cornelson TL, Reed E., Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol. Oncol. 1993, 50:147–158.

20. Pinzani V, Bressolle F, Haug IJ et al., Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother. Pharmacol. 1994, 35:1–9.

21. Jones MM, Basinger MA, Holscher MA, Control of the nephrotoxicity of cisplatin by clinically used sulfur-containing compounds. Fundam. Appl. Toxicol. 1992, 18:181–188.

22. Thulasi G. Pillaia, Mathew Johnb, Gifty Sara Thomasb; Prevention of cisplatininduced nephrotoxicity by terpenes isolated from Ganoderma lucidum occurring in Southern Parts of India; Experimental and Toxicologic Pathology; 2011, 63(1–2):157–160

23. Abdullah Ozkok and Charles L. Edelstein, Pathophysiology of Cisplatin-Induced Acute Kidney Injury; BioMed Research International, 2014, ID 967826, 17.

24. Gihyun Lee, Jun-Ho Lee, KyoungKeun Ham, Hyo Jung Lee, Hyunseong Kim, Hyeonhoon Lee, Moochang Hong, Minkyu Shin, Hyunsu Bae.; Cisplatin induced nephrotoxicity is inhibited by Taxilli Ramulus; Molecular & Cellular Toxicology, 2012, 8(3):311-315

25. Ken Wojcikowski, Lesley Stevenson, David Leach, Hans Wohlmuth, and Glenda Gobe; Antioxidant Capacity of 55 Medicinal Herbs Traditionally Used to Treat The Urinary System: A Comparison Using A Sequential Three-Solvent Extraction Process; The Journal of Alternative and Complementary Medicine, 2007, 13(1): 103–110.

26. Carr, C., Can Ancient Herbs Treat Cancer? Time October, 2007, 15.

27. Aminaljaz et al. Nephroprotective and Antioxidant Effects of Moringa Oleifera (Sohanjna) in Paracetamol Induced Nephrotoxic Albino Rabbits, Pakistan Veterinary Journal, 2016, 292-296

28. Pandey, R.P. & Dilwakar, P.G., An integrated checklist flora of Andaman and Nicobar islands, India. Journal of Economic and Taxonomic Botany, 2008, 32: 403-500.

29. Olson, M. E., Flora of North America Committee, ed. Moringaceae: Drumstick Family. Flora of North America North of Mexico., New York, 2010, pp. 167–169.

30. Iqbal, Shahid; Bhanger, M.I., “Effect of season and production location on antioxidant activity of Moringaoleifera leaves grown in Pakistan”. Journal of Food Composition and Analysis.2006, 19 (6–7): 544–551.

31. Ramachandran, C.; Peter, K. V.; Gopalakrishnan, P. K., 1980, "Drumstick (Moringaoileifera): A multipurpose Indian vegetable". Economic Botany,34 (3): 276–283.

32. Janqueira’s Basic Histology Text & Altas, 2013, In: Anthony L. Mescher, 13th edition, McGrawHill, NY, pp-1-5.

33. Species Plantarum, 1753, 2: 1033.

34. Degras, L., The Yam: A Tropical Root Crop., Wageningen, 1993, pp- 56

35. Flora of China, “huang du”, Dioscoreabulbifera Linnaeus, Sp. Pl., 1753, 2: 1033.

36. Flora of North America, Dioscoreabulbifera Linnaeus, Sp., 1753, Pl. 2: 1033.

37. Practical Pathology and Microbiology, Prof. K. A. Khaleque and Prof. K. Z. Mamun, 2011, pp-147.

38. Practical Manual of Experimental and Clinical Pharmacology, Bikash Medhi and Ajay Prakash, 1st edition, Jaypee Brothers, new Delhi, 2010, pp-23-24.